Ram Ramesh, Morahan Grant
Centre for Diabetes Research, Harry Perkins Institute of Medical Research, Nedlands, WA 6009, Australia.
Centre of Medical Research, University of Western Australia, Nedlands, WA 6009, Australia.
Genes (Basel). 2017 Jun 21;8(6):167. doi: 10.3390/genes8060167.
Genetic studies have identified 61 variants associated with the risk of developing Type 1 Diabetes (T1D). The functions of most of the non-HLA (Human Leukocyte Antigen) genetic variants remain unknown. We found that only 16 of these risk variants could potentially be linked to a protein-coding change. Therefore, we investigated whether these variants affected susceptibility by regulating changes in gene expression. To do so, we examined whole transcriptome profiles of 600 samples from the Type 1 Diabetes Genetics Consortium (T1DGC). These comprised four different immune cell types (Epstein-Barr virus (EBV)-transformed B cells, either basal or after stimulation; and cluster of differentiation (CD)4+ and CD8+ T cells). Many of the T1D-associated risk variants regulated expression of either neighboring (-) or distant (-) genes. In brief, 24 of the non-HLA T1D variants affected the expression of 31 nearby genes () while 25 affected 38 distant genes (). The effects were highly significant (False Discovery Rate < 0.001). In addition, we searched in public databases for expression effects of T1D single nucleotide polymorphisms (SNPs) in other immune cell types such as CD14+ monocytes, lipopolysaccharide (LPS) stimulated monocytes, and CD19+ B cells. In this paper, we review the (expression quantitative trait loci (eQTLs) associated with each of the 60 T1D variants and provide a summary of the genes impacted by T1D risk alleles in various immune cells. We then review the methodological steps involved in analyzing the function of genome wide association studies (GWAS)-identified variants, with emphasis on those affecting gene expression. We also discuss recent advancements in the methodologies and their advantages. We conclude by suggesting future study designs that will aid in the study of T1D risk variants.
基因研究已鉴定出61种与1型糖尿病(T1D)发病风险相关的变异。大多数非人类白细胞抗原(HLA)基因变异的功能仍不清楚。我们发现这些风险变异中只有16种可能与蛋白质编码变化有关。因此,我们研究了这些变异是否通过调节基因表达变化来影响易感性。为此,我们检查了来自1型糖尿病遗传协会(T1DGC)的600个样本的全转录组图谱。这些样本包括四种不同的免疫细胞类型(爱泼斯坦-巴尔病毒(EBV)转化的B细胞,基础状态或刺激后的状态;以及分化簇(CD)4+和CD8+T细胞)。许多与T1D相关的风险变异调节邻近(-)或远处(-)基因的表达。简而言之,24种非HLA T1D变异影响了31个附近基因()的表达,而25种变异影响了38个远处基因()的表达。这些影响非常显著(错误发现率<0.001)。此外,我们在公共数据库中搜索了T1D单核苷酸多态性(SNP)在其他免疫细胞类型中的表达效应,如CD14+单核细胞、脂多糖(LPS)刺激的单核细胞和CD19+B细胞。在本文中,我们回顾了与60种T1D变异中的每一种相关的表达数量性状位点(eQTL),并总结了T1D风险等位基因在各种免疫细胞中影响的基因。然后,我们回顾了分析全基因组关联研究(GWAS)鉴定的变异功能所涉及的方法步骤,重点是那些影响基因表达的步骤。我们还讨论了这些方法的最新进展及其优势。我们通过提出有助于研究T1D风险变异的未来研究设计来得出结论。